手法を比較

	ハンチントン病健康関連QOL尺度 (HD-QoL)	パーキンソン病非運動症状評価尺度 (NMSS)
分野	神経学	神経学
系統	Process / pipeline	Process / pipeline
提唱年	2001	2007
提唱者	Helder et al., University of Leiden	K. Ray Chaudhuri, National Hospital for Neurology and Neurosurgery, London
種類	Self-report questionnaire	Self-report questionnaire and clinician interview
原典	Helder, D. I., Kaptein, A. A., van Kempen, G. M., Weinman, J., van Houwelingen, H. C., & Roos, R. A. (2001). Living with Huntington's disease: Illness perceptions, coping mechanisms, and patients' well-being. Journal of Psychosomatic Research, 50(1), 1-7.	Chaudhuri, K. R., Martinez-Martin, P., Brown, R. G., Sethi, K., Stocchi, F., Odin, P., Ondo, W., Whone, A., Rye, D., Bhattacharya, K., Naidu, Y., Schapira, A. H., Brozova, H., Nutt, J., Macphee, G., Carroll, C., Hilten, J. V., Verschuuren, J., & Bonuccelli, U. (2007). The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 22(13), 1901-1911.
別名	Huntington Disease QoL, HD-QoL Scale	Parkinson's Non-Motor Scale, NMSQ, NMS Scale
関連	4	4
概要	The HD-QoL is a disease-specific quality-of-life instrument designed to measure the multidimensional impact of Huntington's disease on patients' physical, emotional, social, and cognitive functioning. Developed by Helder and colleagues in 2001, it uniquely addresses the progressive motor, cognitive, and psychiatric manifestations characteristic of HD. The scale recognizes that HD burden extends beyond neurological deficits to profound impacts on identity, family relationships, and existential well-being.	The NMSS is a comprehensive 30-item scale designed to assess the prevalence and impact of non-motor symptoms (NMS) in Parkinson's disease. Developed by Chaudhuri and colleagues in 2007, it addresses the reality that non-motor features—sleep disorders, mood disturbances, autonomic dysfunction, cognitive impairment, and pain—often cause greater disability and suffering than motor symptoms in many PD patients. The scale is essential for comprehensive PD assessment and is increasingly recognized as a critical outcome measure reflecting true patient burden.